MIRA Pharmaceuticals' MIRA-55 shows pain relief in preclinical study
Click to view quick news summary (Spoiler)
Preclinical data indicates that MIRA Pharmaceuticals' oral compound MIRA-55 significantly reduced chronic inflammatory pain and paw swelling.
MIRA Pharmaceuticals, Inc. announced results from a 21-day preclinical study evaluating its oral compound MIRA-55 in a chronic inflammatory pain model, according to a company press release.
The study found that once-daily oral MIRA-55 significantly reduced both mechanical and thermal pain hypersensitivity compared with vehicle-treated animals (p < 0.001). At higher doses, the pain-relieving effects were comparable in magnitude to celecoxib (Celebrex), a prescription anti-inflammatory medication. No statistically significant differences were observed between MIRA-55 and celecoxib treatments.
The study, conducted by an independent contract research organization using the Complete Freund's Adjuvant model, included 72 male and female rats. Pain relief was maintained throughout the three-week period with no observed decline in effectiveness, and MIRA-55 reduced inflammation-associated paw swelling to a similar degree as celecoxib. No adverse clinical signs or deaths were reported.
The U.S. Drug Enforcement Administration has determined that MIRA-55 is not a controlled substance. The compound remains in preclinical development, and its safety and efficacy in humans have not been established.
MIRA is targeting an Investigational New Drug (IND) submission for MIRA-55 in the first quarter of 2027, subject to completion of remaining preclinical and regulatory activities. Additional tissue analyses examining inflammatory cytokines and molecular markers are ongoing.
"MIRA-55 demonstrated sustained analgesic activity over repeated low oral daily dosing, without evidence of tolerance, and produced consistent effects in both male and female animals," said Itzchak Angel, Ph.D., Chief Scientific Advisor of MIRA Pharmaceuticals.
The company also has a separate compound, Ketamir-2, advancing toward Phase 2 clinical development for neuropathic pain.
